纳米颗粒131I标记精氨酸-甘氨酸-天冬氨酸-牛血清白蛋白-聚己内酯在肺癌中的抗肿瘤效应
在过表达整合素αvβ3的NCI-H460肺癌细胞及小鼠肺癌模型中,研究131I-RGD-BSA-PCL的靶向结合、细胞内摄取、内照射生物效应及治疗疗效。结果显示该探针肿瘤摄取显著高于其他器官及131I-脂质体,治疗组体重下降仅3.5%(盐水组21.5%),中位生存期延长至27天(131I-BSA-PCL组23天)。
要点
- 131I-RGD-BSA-PCL在过表达整合素αvβ3的NCI-H460肺癌细胞中可见荧光结合,8小时荧光信号未消失。
- 注射后24和72小时肿瘤摄取分别为39.49%±6.06% ID/g和6.97%±1.43% ID/g,显著高于131I-脂质体(p<0.05)。
- 131I-RGD-BSA-PCL治疗组体重下降仅3.5%,远低于盐水组的21.5%,中位生存期延长至27天。
核心结论
- RGD-BSA-PCL在非小细胞肺癌异种移植模型中体外细胞结合良好;131I-RGD-BSA-PCL作为显像剂被评估,是非小细胞肺癌异种移植模型中靶向治疗的有前景候选物。
研究设计与样本
- 研究论文,采用NCI-H460肺癌细胞及小鼠肺癌模型,通过共聚焦显微镜观察靶向结合与细胞摄取,流式细胞术检测凋亡,并监测肿瘤大小、体重、组织病理学及SPECT/CT显像。
关键影像表现/征象
- 共聚焦显微镜显示,与RGD-BSA-PCL或BSA-PCL孵育1小时后细胞内可见荧光,8小时后荧光信号未消失。
- 131I-BSA-PCL注射后24和72小时肿瘤摄取分别为11.06%±2.15% ID/g和3.83%±0.87% ID/g,显著高于其他器官(p<0.05)。
- 131I-RGD-BSA-PCL注射后24和72小时肿瘤摄取分别为39.49%±6.06% ID/g和6.97%±1.43% ID/g,显著高于131I标记脂质体(p<0.05)。
诊断标准与关键数值
- 肿瘤摄取以每克组织注射剂量百分比(% ID/g)表示;131I-BSA-PCL组24小时为11.06%±2.15% ID/g,72小时为3.83%±0.87% ID/g。
- 131I-RGD-BSA-PCL组24小时肿瘤摄取为39.49%±6.06% ID/g,72小时为6.97%±1.43% ID/g,均显著高于131I-脂质体(p<0.05)。
临床应用与阅片要点
- SPECT/CT显像用于监测131I-RGD-BSA-PCL在肿瘤模型中的分布。
- 131I-RGD-BSA-PCL治疗组中位生存期为27天,131I-BSA-PCL组为23天。
- 131I-RGD-BSA-PCL治疗组体重下降为原体重的3.5%,盐水组为21.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of the present study is to investigate the biologic effects of internal irradiation and the therapeutic effectiveness of 131I-labeled arginine-glycine-aspartate (RGD)-bovine serum albumin (BSA)-polycaprolactone (PCL) (131I-RGD-BSA-PCL) in murine lung cancer models.
MATERIALS AND METHODS: The target binding and cellular uptake of NCI-H460 lung cancer cells overexpressing integrin αvβ3 were observed by confocal microscopy. Flow cytometry was used to assay apoptosis. The biologic effects of internal irradiation and the therapeutic efficacy of 131I-RGD-BSA-PCL were investigated in murine lung cancer models; tumor size, body weight, histopathologic findings, and SPECT/CT imaging findings were also monitored.
RESULTS: In vitro uptake studies performed using confocal microscopy showed that, after 1 hour of incubation with RGD-BSA-PCL or BSA-PCL, visible fluorescence was present in the cells, and after 8 hours, the florescent signal did not disappear. The mean (± SE) tumor uptake level (i.e., the percentage of the injected dose per gram of tissue [% ID/g]) of 131I-labeled BSA-PCL (131I-BSA-PCL) at 24 and 72 hours after injection was 11.06% ± 2.15% ID/g and 3.83% ± 0.87% ID/g, respectively, which is significantly higher than the uptake levels noted for other organs (p < 0.05). The level of tumor uptake of 131I-RGD-BSA-PCL at 24 and 72 hours after injection was 39.49% ± 6.06% ID/g and 6.97% ± 1.43% ID/g, respectively, which is significantly higher than that of 131I-labeled liposome (p < 0.05). The decrease in body weight in the group treated with 131I-RGD-BSA-PCL was only 3.5% of the original body weight and was much lower than noted in the group receiving saline (i.e., 21.5% of original body weight). The median survival time for the therapeutic groups was prolonged to 27 days and 23 days after treatment with 131I-RGD-BSA-PCL and 131I-BSA-PCL, respectively.
CONCLUSION: RGD-BSA-PCL has excellent cellular binding in vitro in a non-small cell lung cancer xenograft model. Furthermore, 131I-RGD-BSA-PCL was evaluated as an imaging agent and is an interesting candidate for targeting therapies in the non-small cell lung cancer xenograft model.
引用
- Ming H, Fang L, Gao J, et al. Antitumor Effect of Nanoparticle 131I-Labeled Arginine-Glycine-Aspartate-Bovine Serum Albumin-Polycaprolactone in Lung Cancer. AJR Am J Roentgenol. 2017. PMID: 28301223. doi:10.2214/AJR.16.16947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。